Testosterone therapy for men risk for or with history of prostate cancer

Current Treatment Options in Oncology

Volumn 7, Issue 5, 2006, Pages 363-369

  Morgentaler, Abraham ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GONADORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TESTOSTERONE PROPIONATE;

AUTOPSY; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; DIGITAL RECTAL EXAMINATION; DRUG CONTRAINDICATION; DRUG INFORMATION; DRUG INTERMITTENT THERAPY; DRUG PACKAGING; ESTROGEN THERAPY; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HORMONAL THERAPY; HUMAN; HYPOGONADISM; MALE; PATIENT MONITORING; PROSTATE BIOPSY; PROSTATE CANCER; RECURRENCE RISK; REVIEW; TESTOSTERONE BLOOD LEVEL; UNITED STATES;

ANDROGENS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; PROSTATIC NEOPLASMS; RISK; TESTOSTERONE;

EID: 33748375790     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-006-0004-y     Document Type: Review

References (27)

1. Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1:293-297.
2. Physician's Desk Reference. Montvale, NJ: Thomson PDR; 2005:3245.
3. Gaylis FD, Lin DW, Ignatoff JM, et al.: Prostate cancer in men using testosterone supplementation. J Urol 2005, 174:534-538.
4. Rhoden EL, Morgentaler A: Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004, 350:482-492.
5. Gould DC, Kirby RS: Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer? Prostate Cancer Prostatic Dis 2006, 9:14-18.
6. Bhasin S, Singh AB, Mac RP, et al.: Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003, 24:299-311.
7. Morgentaler A: Testosterone replacement therapy and prostate risks: where's the beef? Can J Urol 2006, 13:S40-S43.
8. Barqawi AB, Crawford ED: Testosterone replacement therapy and the risk of prostate cancer: a perspective view. Int J Impot Res 2005, 17:462-463.
9. Kaufman JM, Graydon RJ: Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004, 172:920-922.
10. Agarwal PK, Oefelein MG: Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005, 173:533-536.
11. Prout GR, Brewer WR: Response of men with advanced prostatic carcinoma to exogenous administration of testosterone. Cancer 1967, 20:1871-1878.
12. Fowler JE, Whitmore WF Jr: The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981, 126:372-375.
13. Sakr WA, Grignon DJ, Crissman JD, et al.: High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994, 8:439-443.
14. Hsing AW: Hormones and prostate cancer: what's next? Epidemiol Rev 2001, 23:42-58.
15. Parsons JK, Carter HB, Platz EA, et al.: Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidermiol Biomarkers Prev 2005 14:2257-2260.
16. Statin P, Lumme S, Tenkanen L, et al.: High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 2004, 108:418-424.
17. Chen C, Weiss NS, Stanczyk FZ, et al.: Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 2003, 12:1410-1416.
18. Platz EA, Leitzmann MF, Rifai N, et al.: Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomakers Prev 2005, 14:1262-1269.
19. Gann PH, Hennekens CH, Ma J, et al.: Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996, 88:1118-1126.
20. Rhoden EL, Morgentaler A: Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 2003, 170:2348-2351.
21. Lefkowitz GK, Taneja SS, Brown J, et al.: Follow-up interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. J Urol 2002, 168:1415-1418.
22. Morgentaler A, Bruning CO III, DeWolf WC: Incidence of occult prostate cancer among men with low total or free serum testosterone. JAMA 1996, 276:1904-1906.
23. Thompson IM, Pauler DK, Goodman PJ etal.: Prevalence of prostate cancer among men with a prostate-specific antigen level less than or equal to 4 ng per milliliter. N Eng J Med 2004, 350:2239-2246.
24. Bubley GJ: Is the flare phenomenon clinically significant? Urology 2001, 58(Suppl 2A):5-9.
25. Kuhn JM, Billebaud T, Navratil H, et al.: Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (Buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (Nilutamide). N Engl J Med 1989, 321:413-418.
26. Tomera K, Gleason D, Gittelman M, et al.: The gonadotropin-releasing hormone antagonist Abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001, 16:1585-1589.
27. Sato N, Akakura K, Isaka S, et al.: Chiba Prostate Study Group. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology 2004, 64:341-345.